It is intriguing to hypothesize that neurofibromin-deficient monocytes recruited during this window give rise to infiltrating macrophages that drive the pathogenesis of NF1 arteriopathy and therefore targeted MEK inhibition during this window is more effective than early treatment. Here, MAP2K7 is linked to neurofibromatosis type 1.